O-023 Stroke predictX: a tissue-based clinical decision tool to predict stroke outcomes after endovascular therapy

ConclusionsOur pre-and post-procedural models reliably estimated clinical outcomes in stroke patients undergoing thrombectomy. They represent a step forward in creating simple and efficient prognostication tools to aid treatment decision-making.Disclosures M. Bouslama: None. L. Pisani: None. D. Haussen: 2; C; Stryker, Vesalio, Cerenovus, and Jacobs Institute. 4; C; VizAi. R. Nogueira: 1; C; PI of ENDOLOW trial. Funding provided by Cerenovus. 2; C; consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby. 3; C; Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze.
Source: Journal of NeuroInterventional Surgery - Category: Neurosurgery Authors: Tags: SNIS 19th annual meeting oral abstracts Source Type: research